[1]
|
M. Dimopoulos, E. Terpos, R. L. Comenzo, et al., “International Myeloma Working Group Consensus Statement and Guidelines Regarding the Current Role of Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma,” Leukemia, Vol. 23, 2009, pp. 1545-1556. doi:10.1038/leu.2009.89
|
[2]
|
B. G. Durie, R. A. Kyle, A. Belch, et al., “Myeloma Man- agement Guidelines: A Consensus Report from the Scientific Advisors of the International Myeloma Foundation,” Hematology Journal, Vol. 4, 2003, pp. 379-398.
doi:10.1038/sj.thj.6200312
|
[3]
|
D. M. Weber, M. Dimopoulos, L. A. Moulopoulos, et al., “Prognostic Features of Asymptomatic Multiple Myeloma,” British Journal of Hematology, Vol. 97, No. 4, 1996, pp. 810-814.
doi:10.1046/j.1365-2141.1997.1122939.x
|
[4]
|
F. E. Lecouvet, B. C. Vande Berg, J. Malghem & B. E. Maldague, “Magnetic Resonance and Computed Tomo- graphy Imaging in Multiple Myeloma,” Seminars in Musculoskeletal Radiology, Vol. 5, No. 1, 2001, pp. 43- 55. doi:10.1055/s-2001-12920
|
[5]
|
A. Baur-Melnyk, S. Buhmann, C. Becker, et al., “Whole-Body MRI versus Whole-Body MDCT for Staging of Multiple Myeloma,” American Journal of Roentgenology, Vol. 190, No. 4, 2008, pp. 1097-1104.
doi:10.2214/AJR.07.2635
|
[6]
|
M. Horger, L. Kanz, B. Denecke, et al., “The Benefit of Using Whole-Body, Low-Dose, Nonenhanced, Multidetector Computed Tomography for Follow-Up and Therapy Response Monitoring in Patients Whit Multiple Myeloma,”, Cancer, Vol. 109, No. 8, 2007, pp. 1617-1626. doi:10.1002/cncr.22572
|
[7]
|
F. Wisloff, P. Andersen, T. R. Andersson, et al., “Incidence and Follow-Up of Asymptomatic Multiple Myeloma. The Myeloma Project of Health Region I in Norway,” European Journal of Haematology, Vol. 47, No. 5, 1991, pp. 338-341.
doi:10.1111/j.1600-0609.1991.tb01857.x
|
[8]
|
A. Baur-Melnyk and M. Reiser, “Staging of Multiple Myeloma with MRI: Comparison to MSCT and Conventional Radiography,” Radiologe, Vol. 44, No. 9, 2004, pp. 874-881.
|
[9]
|
M. Dimopoulos, P. G. Richardson, N. Brandenburg, et al., “A Review of Second Primary Malignancy in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide,” Blood, Vol. 119, No. 12, 2012, pp. 2764-2767. doi:10.1182/blood-2011-08-373514
|